Some users experience diarrhea, others constipation, and some alternate between both
GHK-Cu modulates the immune system, which is unpredictable in an autoimmune state
Research scenario Better conceptual fit Reason Testing GLP-1 plus satiety-pathway extension CagriSema Combines semaglutide with amylin analog activity Testing maximum receptor breadth Retatrutide Activates GIP, GLP-1, and glucagon receptors Studying diabetes plus obesity together Both Both have programs relevant to T2D and weight Comparing incremental vs radical next-gen strategy Both CagriSema extends GLP-1
Seek medical advice if any side effects are prolonged or painful
Patients do not self-select their peptides or doses
Pastore, A., Federici, G., Bertini, E